Takeda's fruquintinib receives positive CHMP opinion for metastatic colorectal cancer treatment.
Takeda received a positive CHMP opinion for fruquintinib in previously treated metastatic colorectal cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended fruquintinib's approval for adult patients with metastatic CRC. The European Commission will consider the positive opinion when determining marketing authorization for fruquintinib in the EU, Norway, Liechtenstein, and Iceland.
April 26, 2024
3 Articles